Allogeneic Cell Therapies Summit Europe

Memo

Address Key European Regulatory Challenges and Cutting Edge Platform Design to Advance Allogeneic Approaches Allogeneic therapies are fast becoming the holy grail for cell therapy as they boast the potential to reduce the cost of goods, improve accessibility, reduce turnaround times and have the ability to treat masses of patients. However, in Europe there are critical challenges limiting clinical advancement, with increased complexities with disharmonized European regulations where guidance varies across countries, and challenges in cross-country logistics when running multicentric trials. The Allogeneic Cell Therapies Summit Europe is the only industry-focused forum dedicated to address the specific challenges facing European drug developers in order to advance your pipeline to clinical and commercial success. Collaborate with European leaders from Cellectis, Celyad, GammaDelta Therapeutics, Medicines and Healthcare Products Regulatory Agency and more to benchmark best-in-class approaches to achieve optimal clinical set up and large scale manufacture for your off-the-shelf product. Ensure you have these important considerations planned early in development to overcome delays and critical push backs later in your clinical translation. Join your community in London this January to take on this next frontier in cell therapy and leave with cutting-edge strategies to develop safe, effective and accessible cell therapies for patients in Europe. This is your comprehensive guide to define your commercial path forward developing off-the-shelf products. https://allogeneic-cell-therapies-europe.com/18-20 January, 2022London, UK Contact:This email address is being protected from spambots. You need JavaScript enabled to view it. Brochure https://go.evvnt.com/925458-0?pid=5569,Tickets https://go.evvnt.com/925458-1?pid=5569 Prices:Drug Developers (Earlybird rates & workshops available) GBP 2599.00Academic (Earlybird rates & workshops available) GBP 2099.00Service Providers (Earlybird rates & workshops available) GBP 2999.00 Speakers: Miguel Forte, CEO, Bone Therapeutics, André Choulika, CEO, Cellectis, Vicki Coutinho, VP of Regulatory Affairs & Quality, GammaDelta Therapeutics, Troels Jordansen, CEO, Glycostem Therapeutics, Kimberly Schluns, Senior Director, Research, Kite Pharma, John Johnston, Clinical Assessor, MHRA Date and Time: Starts: Tue, Jan 18, 2022 ( 8:00 AM) and Ends: Thu, Jan 20, 2022 ( 6:00 PM) Venue details: Amba Marble Arch (Guoman), Bryanston Street, Greater London, England, W1H 7EH, United Kingdom